Marktinformationen

21.06.2024 14:05:06 - dpa-AFX: *TAKEDA CANADA GETS APPROVAL FOR HYQVIA AS PRIMARY & SECONDARY IMMUNODEFICIENCY REPLACEMENT THERAPY IN PEDIATRIC PATIENTS

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
TAKEDA PHARM.CO.LTD. 853849 Frankfurt 24,310 05.07.24 21:49:39 +0,190 +0,79% 24,270 24,390 24,270 24,310

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH